Text
The acquisition will enhance its ability to address the needs of a growing market, empowering researchers and industries worldwide.
The live biotherapeutics market is forecasted to exceed $4 billion by 2030, driven by advancements like MaaT013.
Its emergence in the respiratory health sector represents a paradigm shift, offering promising avenues for innovation and investment.
Targeting L-kynurenine metabolism could be a therapeutic strategy for managing Crohn’s disease.
The findings suggest that the composition of the gut microbiota in early life is not a key factor in obesity risk.
New research has now uncovered differences in the gut microbiota composition between people with the condition and those without.
Specific gut microbiota features correlate with better responses to immunotherapy in people with melanoma.
The study revealed that MS-20 dramatically improved treatment outcomes, tripling the objective response rate (ORR) to 75% when combined with Keytruda.
Including microbial load in microbiota studies can help researchers better understand how gut bacteria influence diseases, leading to more accurate diagnoses and effective treatments.
The findings highlight the importance of maintaining a healthy microbiota after EEN and suggest that personalized dietary approaches can help induce remission for children with Crohn’s disease.
